SCHEMBL5129270

SCHEMBL5129270

CCCOc1nc2ccccn2c(=O)c1-c1ccc(N[C@@H]2CCN(C(=O)OC(C)(C)C)C2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.42
KCNK3 O14649 3/20 0.42
KCNK9 Q9NPC2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
GFER P55789 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
MET P08581 1/20 0.40
BTK Q06187 1/20 0.39
PARP1 P09874 1/20 0.39
PIK3CD O00329 1/20 0.39
PRMT5 O14744 1/20 0.38
POLR1A O95602 1/20 0.38
MERTK Q12866 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5129264 1.00 USP30 (0.42) USP30KCNK3KCNK9ALDH1A1GFER
SCHEMBL5128665 0.90 ALDH1A1 (0.49) USP30KCNK3KCNK9ALDH1A1GFER
SCHEMBL3955167 0.90 GFER (0.44) KCNK3KCNK9ALDH1A1GFERL3MBTL1
SCHEMBL5129445 0.88 ALDH1A1 (0.43) USP30KCNK3KCNK9ALDH1A1GFER
SCHEMBL5129442 0.88 ALDH1A1 (0.43) USP30KCNK3KCNK9ALDH1A1GFER
SCHEMBL5128596 0.88 ALDH1A1 (0.44) USP30KCNK3KCNK9ALDH1A1GFER
SCHEMBL5128594 0.88 ALDH1A1 (0.44) USP30KCNK3KCNK9ALDH1A1GFER
SCHEMBL4172559 0.87 ALDH1A1 (0.44) USP30KCNK3KCNK9ALDH1A1GFER
SCHEMBL5125838 0.86 ALDH1A1 (0.46) USP30KCNK3KCNK9ALDH1A1GFER
SCHEMBL5125842 0.86 ALDH1A1 (0.46) USP30KCNK3KCNK9ALDH1A1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194616-A1 PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-14 US claimed
US-20080194616-A1 PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-14 US disclosed
US-20080194616-A1 PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-14 US disclosed
US-20080194616-A1 PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-14 US disclosed
WO-2008097991-A1 PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194616-A1 PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS SCN1A, SCN3A, SCN1B USP30 4715/4885KCNK3 56/4885KCNK9 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.